Drug updated on 11/16/2023

Dosage FormInjection (subcutaneous: 2 mg/1.5 mL, 4 mg/3 mL, 8 mg/3 mL)
Drug ClassGlucagon-like peptide 1 (GLP-1) receptor agonists
Ongoing and Completed StudiesClinicalTrials.gov


  • Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
  • Indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease.

Product Monograph / Prescribing Information

Document TitleYearSource
Ozempic (semaglutide) Prescribing Information.2022Novo Nordisk Inc., Plainsboro, NJ

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Efficacy and safety of oral semaglutide in type 2 diabetes mellitus: A systematic review and meta-analysis2023Diabetes Research and Clinical Practice
GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials2023Journal of Clinical Endocrinology & Metabolism
Real-world clinical effectiveness of once-weekly semaglutide in patients with type 2 diabetes: a systematic literature review2023Expert Review of Clinical Pharmacology
Assessment report: Ozempic. 2022EMA
Semaglutide for the treatment of type 2 Diabetes Mellitus: a systematic review and network meta-analysis of safety and efficacy outcomes.2022Diabetes & Metabolic Syndrome
The efficacy and safety of oral semaglutide for glycaemic management in adults with type 2 diabetes compared to subcutaneous semaglutide, placebo, and other GLP-1 RA comparators: A systematic review and network meta-analysis. 2022Contemporary Clinical Trials Communication
An Indirect Treatment Comparison of Semaglutide 2.0 mg vs Dulaglutide 3.0 mg and 4.5 mg Using Multilevel Network Meta-regression2022Journal of Clinical Endocrinology & Metabolism
Medications for obesity management: effectiveness and value.2022ICER
Comparative efficacy of glucagon-like peptide 1 receptor agonists and sodium glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular events in type 2 diabetes: a network meta-analysis.2021Journal of Cardiovascular Pharmacology
Comparison of the effects of 10 GLP-1 RA and SGLT2 inhibitor interventions on cardiovascular, mortality, and kidney outcomes in type 2 diabetes: a network meta-analysis of large randomized trials.2021Primary Care Diabetes
Once-daily oral semaglutide versus injectable glp-1 ras in people with type 2 diabetes inadequately controlled on basal insulin: systematic review and network meta-analysis.2021Diabetes Therapy
Comparative efficacy and safety of 8 GLP-1RAs in patients with type 2 diabetes: A network meta-analysis.2021Diabetes Research and Clinical Practice
Australian public assessment report for semaglutide.2020Australian Government: Department of Health
Clinical review report: semaglutide (Ozempic).2019CADTH
Oral semaglutide for type 2 diabetes: effectiveness and value.2019ICER
Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.2018Frontiers in Pharmacology

Clinical Practice Guidelines